Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib

Acquired drug resistance impacts the majority of patients being treated with tyrosine kinase inhibitors (TKIs) and remains a key challenge in modern anti-cancer therapy. The lack of clinically effective therapies to overcome resistance represents an unmet need. Understanding the signalling that driv...

Descripción completa

Detalles Bibliográficos
Autores principales: Vyse, Simon, McCarthy, Frank, Broncel, Malgorzata, Paul, Angela, Wong, Jocelyn P., Bhamra, Amandeep, Huang, Paul H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673060/
https://www.ncbi.nlm.nih.gov/pubmed/28842319
http://dx.doi.org/10.1016/j.jprot.2017.08.015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673060/
https://www.ncbi.nlm.nih.gov/pubmed/28842319
http://dx.doi.org/10.1016/j.jprot.2017.08.015

Ejemplares similares